november Aktiengesellschaft

EANS-News: november Aktiengesellschaft

@@start.t1@@--------------------------------------------------------------------------------   Corporate news transmitted by euro adhoc. The issuer/originator is solely   responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

6-month report

Köln (euro adhoc) - Half-Year Results 2010 Confirm: november AG On Target Publication of consolidated operating results as of June 30, 2010

•          PROGEN Biotechnik GmbH achieves positive operating results
•          Stable revenues of TEUR 1.806
•          Consulting expenses halved
•          For the first time, nearly balanced financial results

Preliminary figures of the consolidated half-years results per June 30, 2010 of the november AG and its principal subsidiaries and participations confirm target figures for 2010. Particularly encouraging is the positive preliminary IFRS operating result of TEUR 73 of the operative subsidiary PROGEN Biotechnik GmbH, thereby not taking in account the positive effect of loan wavers. The preliminary consolidated sales of TEUR 1.806 are also well within budget figures. Consulting expenses were almost halved as compared to the same period last year from TEUR 344 to approx. TEUR 181, despite additional due diligence expenditures and costs for the evaluation of legal claims. Also the almost balanced financial results of the preliminary consolidated operating statement are an indication for a continuing positive development of the november AG.

For further information, we refer to our half-year-report 2010, published on our homepage: http://www.november.eu/company-profile/reports.html

@@start.t2@@end of announcement                                                 euro adhoc
--------------------------------------------------------------------------------@@end@@

ots Originaltext: november Aktiengesellschaft
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Christoph Schmitz
Leiter Finanzen, Controlling
Tel.: +49 (0) 221- 820 05 20 -10
E-Mail: info@november.de

Branche: Biotechnology
ISIN:      DE000A0Z24E9
WKN:        A0Z24E
Index:    CDAX, Prime All Share, Technology All Share
Börsen:  Frankfurt / regulated dealing/prime standard
              Berlin / free trade
              Stuttgart / free trade
              Düsseldorf / free trade
              Hannover / free trade
              München / free trade



Weitere Meldungen: november Aktiengesellschaft

Das könnte Sie auch interessieren: